Mycotrienins. A new class of potent inhibitors of osteoclastic bone resorption.
Pharmacological intervention using selective tyrosine kinase inhibitors has been shown to be an effective approach to inhibit osteoclast function. Here, we report on the structure-activity relations of benzoquinone ansamycins isolated from Streptomyces rishirensis, which form a new class of potent inhibitors of osteoclast-mediated bone resorption. Parathyroid hormone-stimulated bone resorption was inhibited concentration dependently by both mycotrienin I and mycotrienin II, showing half-maximal inhibition in the low nanomolar range in fetal rat long bones in vitro. Structure-activity relation studies indicate that position 19 contained within the quinone/hydroquinone element and the double bonds in position 4, 6, and 8 are crucial for full bioactivity. In contrast, substitutions in position 22 are well tolerated. The lack of a similar effect of 2,6-dimethyl-p-benzoquinone and vitamin K signifies that the mechanism of action is not solely due to the oxygen scavenger capacity of the quinone/hydroquinone moiety. The inhibition of osteoclastic bone resorption is in line with the diminished activity of immunopurified pp60c-src from bone suggesting that pp60c-src is a possible target of mycotrienins in the organ culture. Thus, mycotrienins may be useful as pharmacologic inhibitors of osteoclastic bone resorption.
Feuerbach
D
D
Department of Bone & Joints, Sandoz Pharma Limited, Basel, Switzerland.
Waelchli
R
R
Fehr
T
T
Feyen
J H
JH
D000818:Animals; D016227:Benzoquinones / Q000494:pharmacology* / Q000633:toxicity; D001862:Bone Resorption / Q000139:chemically induced*; D001842:Bone and Bones / Q000187:drug effects* / Q000196:embryology; D004305:Dose-Response Relationship, Drug; D006873:Hydroquinones / Q000737:chemistry / Q000494:pharmacology / Q000633:toxicity; D047029:Lactams, Macrocyclic; D009924:Organ Culture Techniques; D010010:Osteoclasts / Q000187:drug effects; D010281:Parathyroid Hormone / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000187:drug effects; D011809:Quinones / Q000494:pharmacology / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D017828:Rifabutin / Q000031:analogs & derivatives*; D012294:Rifamycins; D013329:Structure-Activity Relationship; D010837:Vitamin K 1 / Q000494:pharmacology
D016227:Benzoquinones; D006873:Hydroquinones; D047029:Lactams, Macrocyclic; D010281:Parathyroid Hormone; D011809:Quinones; D012294:Rifamycins; D017828:Rifabutin; C020754:herbimycin; C036970:mycotrienin I; C036971:mycotrienin II; D010837:Vitamin K 1; D011505:Protein-Tyrosine Kinases; D016392:Proto-Oncogene Proteins pp60(c-src)